Skye Bioscience, Inc. – OTC:SKYE

Skye Bioscience stock price today

$3.25
+0.79
+32.11%
Financial Health
0
1
2
3
4
5
6
7
8
9

Skye Bioscience stock price monthly change

-61.80%
month

Skye Bioscience stock price quarterly change

-61.80%
quarter

Skye Bioscience stock price yearly change

-3.53%
year

Skye Bioscience key metrics

Market Cap
38.08M
Enterprise value
7.71M
P/E
-0.4
EV/Sales
N/A
EV/EBITDA
-0.31
Price/Sales
N/A
Price/Book
-2.95
PEG ratio
N/A
EPS
-4.51
Revenue
N/A
EBITDA
-16.13M
Income
-37.49M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Skye Bioscience stock price history

Skye Bioscience stock forecast

Skye Bioscience financial statements

Skye Bioscience, Inc. (OTC:SKYE): Profit margin
Jun 2023 0 -3.11M
Sep 2023 0 -24.94M
Dec 2023 191.76K -4.41M -2304.93%
Mar 2024 0 -5.01M
Skye Bioscience, Inc. (OTC:SKYE): Analyst Estimates
2025 0 -33.31M
2026 0 -44.26M
  • Analysts Price target

  • Financials & Ratios estimates

Skye Bioscience, Inc. (OTC:SKYE): Debt to assets
Jun 2023 2235944 10.02M 448.36%
Sep 2023 15604330 13.90M 89.14%
Dec 2023 11940411 14.07M 117.85%
Mar 2024 94835276 15.95M 16.82%
Skye Bioscience, Inc. (OTC:SKYE): Cash Flow
Jun 2023 -1.99M 0 -123.41K
Sep 2023 -4.05M 1.07M 16.63M
Dec 2023 -3.84M -7.01K -22.65K
Mar 2024 -4.70M 1.14M 85.65M

Skye Bioscience alternative data

Skye Bioscience, Inc. (OTC:SKYE): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Mar 2024 11
Apr 2024 11
May 2024 11
Jun 2024 11
Jul 2024 11

Skye Bioscience other data

0.00% -0.00%
of SKYE is owned by hedge funds
11.9K +0
shares is hold by hedge funds

Skye Bioscience, Inc. (OTC:SKYE): Insider trades (number of shares)
Period Buy Sel
Jan 2024 5206074 0
Mar 2024 450000 0
Sep 2024 0 532674
Nov 2024 0 232431
Transaction Date Insider Security Shares Price per share Total value Source
Sale
DIEP TUAN TU officer: Chief Development Offi..
Common Stock 19,489 $4.99 $97,250
Sale
ARSENAULT KAITLYN officer: Chief Financial Officer
Common Stock 43,206 $4.99 $215,598
Sale
DHILLON PUNIT director, officer: Chief Execut..
Common Stock 82,546 $4.99 $411,905
Sale
GRAYSON PAUL A. director
Common Stock 86,244 $4.99 $430,358
Sale
DIEP TUAN TU officer: Chief Development Offi..
Common Stock 85 $5.55 $472
Sale
ARSENAULT KAITLYN officer: Chief Financial Officer
Common Stock 190 $5.55 $1,055
Sale
DHILLON PUNIT director, officer: Chief Execut..
Common Stock 364 $5.55 $2,020
Sale
GRAYSON PAUL A. director
Common Stock 307 $5.55 $1,704
Sale
SCHWAB ANDREW J. director, 10 percent owner:
Common Stock 11,758 $6.06 $71,253
Sale
SCHWAB ANDREW J. director, 10 percent owner:
Common Stock 2,000 $6.06 $12,120
Thursday, 19 December 2024
globenewswire.com
Tuesday, 10 December 2024
seekingalpha.com
Thursday, 14 November 2024
globenewswire.com
Thursday, 7 November 2024
seekingalpha.com
globenewswire.com
Friday, 1 November 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Wednesday, 9 October 2024
marketbeat.com
Friday, 4 October 2024
marketbeat.com
Wednesday, 4 September 2024
seekingalpha.com
Monday, 26 August 2024
globenewswire.com
Friday, 23 August 2024
globenewswire.com
Thursday, 22 August 2024
globenewswire.com
Wednesday, 21 August 2024
accesswire.com
Tuesday, 20 August 2024
accesswire.com
Monday, 19 August 2024
globenewswire.com
accesswire.com
accesswire.com
Sunday, 18 August 2024
accesswire.com
Saturday, 17 August 2024
accesswire.com
Friday, 16 August 2024
accesswire.com
accesswire.com
Thursday, 15 August 2024
accesswire.com
accesswire.com
Wednesday, 14 August 2024
accesswire.com
accesswire.com
accesswire.com
Tuesday, 13 August 2024
globenewswire.com
accesswire.com
accesswire.com
  • What's the price of Skye Bioscience stock today?

    One share of Skye Bioscience stock can currently be purchased for approximately $3.25.

  • When is Skye Bioscience's next earnings date?

    Unfortunately, Skye Bioscience's (SKYE) next earnings date is currently unknown.

  • Does Skye Bioscience pay dividends?

    No, Skye Bioscience does not pay dividends.

  • How much money does Skye Bioscience make?

    Skye Bioscience has a market capitalization of 38.08M.

  • What is Skye Bioscience's stock symbol?

    Skye Bioscience, Inc. is traded on the OTC under the ticker symbol "SKYE".

  • What is Skye Bioscience's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Skye Bioscience?

    Shares of Skye Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Skye Bioscience have?

    As Jul 2024, Skye Bioscience employs 11 workers.

  • When Skye Bioscience went public?

    Skye Bioscience, Inc. is publicly traded company for more then 4 years since IPO on 1 Jun 2021.

  • What is Skye Bioscience's official website?

    The official website for Skye Bioscience is skyebioscience.com.

  • Where are Skye Bioscience's headquarters?

    Skye Bioscience is headquartered at 5910 Pacific Center Boulevard, San Diego, CA.

  • How can i contact Skye Bioscience?

    Skye Bioscience's mailing address is 5910 Pacific Center Boulevard, San Diego, CA and company can be reached via phone at +94 94809051.

Skye Bioscience company profile:

Skye Bioscience, Inc.

skyebioscience.com
Exchange:

OTC

Full time employees:

9

Industry:

Biotechnology

Sector:

Healthcare

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.

5910 Pacific Center Boulevard
San Diego, CA 92130

CIK: 0001516551
:
: